Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.

Planchard D, Jänne PA, Yang JC, Kobayashi K, Valdiviezo N, Fan Y, Kim TM, Gálvez ML, Nishino K, Biswas B, Feng PH, Sriuranpong V, Koubkova L, Pinto GDJ, Escriu C, Tran TV, Takahashi T, Nerón Y, Han JY, Figueroa A, Donachie V, Khullar A, Evans A, Albayaty M, Lee CK

Open source

DOI: 10.1016/j.lungcan.2026.109588
Published: 2026 Sep 14
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109588,
  title = {Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.},
  author = {Planchard D and Jänne PA and Yang JC and Kobayashi K and Valdiviezo N and Fan Y and Kim TM and Gálvez ML and Nishino K and Biswas B and Feng PH and Sriuranpong V and Koubkova L and Pinto GDJ and Escriu C and Tran TV and Takahashi T and Nerón Y and Han JY and Figueroa A and Donachie V and Khullar A and Evans A and Albayaty M and Lee CK},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109588},
  url = {https://doi.org/10.1016/j.lungcan.2026.109588}
}

RIS

TY  - JOUR
TI  - Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
AU  - Planchard D
AU  - Jänne PA
AU  - Yang JC
AU  - Kobayashi K
AU  - Valdiviezo N
AU  - Fan Y
AU  - Kim TM
AU  - Gálvez ML
AU  - Nishino K
AU  - Biswas B
AU  - Feng PH
AU  - Sriuranpong V
AU  - Koubkova L
AU  - Pinto GDJ
AU  - Escriu C
AU  - Tran TV
AU  - Takahashi T
AU  - Nerón Y
AU  - Han JY
AU  - Figueroa A
AU  - Donachie V
AU  - Khullar A
AU  - Evans A
AU  - Albayaty M
AU  - Lee CK
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109588
UR  - https://doi.org/10.1016/j.lungcan.2026.109588
ER  -

APA

D, P., PA, J., JC, Y., K, K., N, V., Y, F., TM, K., ML, G., K, N., B, B., PH, F., V, S., L, K., GDJ, P., C, E., TV, T., T, T., Y, N., JY, H., A, F., V, D., A, K., A, E., M, A., & CK, L. (2026). Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109588

Source records

pubmed · retrieved 2026-09-25T20:56:23.559Z